State Street Corp Purchases 19,800 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)

State Street Corp raised its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 21.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 111,907 shares of the company’s stock after purchasing an additional 19,800 shares during the quarter. State Street Corp owned 0.15% of Context Therapeutics worth $219,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CNTX. Renaissance Technologies LLC increased its position in shares of Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares in the last quarter. Ally Bridge Group NY LLC raised its stake in shares of Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Context Therapeutics during the second quarter valued at $3,881,000. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Context Therapeutics during the second quarter valued at $4,527,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX opened at $1.25 on Friday. The stock’s 50-day simple moving average is $1.58 and its two-hundred day simple moving average is $1.96. The stock has a market capitalization of $93.75 million, a price-to-earnings ratio of -1.37 and a beta of 2.00. Context Therapeutics Inc. has a 52-week low of $0.89 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, equities analysts forecast that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. D. Boral Capital began coverage on Context Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a report on Monday, September 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $6.80.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.